Literature DB >> 3817074

No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid.

I A Cotgreave, A Eklund, K Larsson, P W Moldéus.   

Abstract

Six healthy volunteers underwent bronchoalveolar lavage (BAL) before and after receiving N-acetylcysteine (NAC) 600 mg daily for 2 weeks. Free and total NAC, cysteine and glutathione were determined in the lavage fluid, lavage cells and plasma. No NAC was demonstrated, free or bound in disulfides, in either of the lavage components; furthermore, the cysteine and glutathione content of these components and their respective redox states were unaltered during therapy. Plasma free and total cysteine content was unaltered by administration of the drug, but both free and total plasma glutathione increased significantly. Free NAC could not be detected in plasma following dosing. However, a mean of 0.3 nmol/100 microliters plasma was released from disulfides in plasma following reduction with dithiothreitol. N-acetylcysteine has been proposed to act as a mucolytic by cleavage of disulfide bonds. Our findings do not support this direct mode of action and alternative mechanisms of action must be sought.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3817074

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  22 in total

Review 1.  [Good sense and nonsense of antitussive agents].

Authors:  A Gillissen; S Tasci; S Ewig; H Schäfer; S Zielen
Journal:  Internist (Berl)       Date:  2001-01       Impact factor: 0.743

Review 2.  Mucolytics: when dispensable, when necessary?

Authors:  P Dorow
Journal:  Lung       Date:  1990       Impact factor: 2.584

3.  Lung lining fluid glutathione attenuates IL-13-induced asthma.

Authors:  Matthew H Lowry; Brian P McAllister; Jyh-Chang Jean; Lou Ann S Brown; Rebecca P Hughey; William W Cruikshank; Sal Amar; Edgar C Lucey; Kathleen Braun; Pamela Johnson; Thomas N Wight; Martin Joyce-Brady
Journal:  Am J Respir Cell Mol Biol       Date:  2007-12-06       Impact factor: 6.914

4.  The Effect of Cigarette Smoke-derived Oxidants on the Inflammatory Response of the Lung.

Authors:  Robert Foronjy; Jeanine D'Armiento
Journal:  Clin Appl Immunol Rev       Date:  2006-01-01

Review 5.  Oxidants/antioxidants in idiopathic pulmonary fibrosis.

Authors:  W MacNee; I Rahman
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

Review 6.  Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.

Authors:  Julian Tam; Edward F Nash; Felix Ratjen; Elizabeth Tullis; Anne Stephenson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-12

7.  Comparative evaluation of N-acetylcysteine (NAC) and N-acetylcysteine amide (NACA) on glutamate and lead-induced toxicity in CD-1 mice.

Authors:  Suman Penugonda; Nuran Ercal
Journal:  Toxicol Lett       Date:  2010-12-09       Impact factor: 4.372

8.  Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine.

Authors:  M M Bridgeman; M Marsden; W MacNee; D C Flenley; A P Ryle
Journal:  Thorax       Date:  1991-01       Impact factor: 9.139

Review 9.  Role of N-acetylcysteine in the management of COPD.

Authors:  Anna M Sadowska; J Verbraecken; K Darquennes; W A De Backer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  The role for N-acetylcysteine in the management of COPD.

Authors:  P N R Dekhuijzen; W J C van Beurden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.